AIM ImmunoTech Inc.
AIM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AIM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AIM
AIM ImmunoTech Inc. is a clinical-stage biopharmaceutical company focused on developing its lead investigational drug, Ampligen, for viral diseases and cancers, with no approved products and a history of operating losses.
Key risk: Regulatory approval risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$7.9M
Cash Runway
6.6 moLead Asset
alferon n (Approved)
Next Catalyst
Phase2_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 9 clinical trials · 2 catalysts for AIM ImmunoTech Inc..
AIM ImmunoTech Inc. is a clinical-stage biopharmaceutical company focused on developing its lead investigational drug, Ampligen, for viral diseases and cancers, with no approved products and a history of operating losses.
- Lead product candidate is Ampligen, an investigational drug for viral diseases and cancers, with no FDA approval to date [sec].
- Cash and equivalents of $9.9M as of 2026-06-30, with total debt of $7.2M and negative shareholders' equity of -$9.8M [sec].
- Net loss of -$3.8M for the period ending 2026-06-30, with zero total revenue [sec].
- Company faces significant uncertainty regarding future financing and the success of clinical trials [sec].
- Upcoming catalysts include a Phase 2 topline readout for Ampligen by 2026-12-31 and a Phase 3 topline for ropivacaine by 2028-09-01 [catalyst].
What works
- Ampligen is being investigated as a broad-spectrum prophylactic or early-onset treatment for viral threats, including Ebola and coronaviruses, based on preclinical proof-of-concept findings [sec · filed 2026-08-11].
- The company has multiple ongoing or planned clinical trials, including a Phase 2 study for Ampligen and a Phase 3 study for ropivacaine, indicating active pipeline development [catalyst].
What to weigh
- The company has no approved products and its drug candidates are investigational, requiring significant additional testing and regulatory approval [sec · filed 2026-02-05].
- AIM ImmunoTech has incurred substantial losses and its future profitability is uncertain, with a net loss of -$3.8M and negative shareholders' equity as of 2026-06-30 [sec].
- The company will require additional financing, which may not be available, and faces risks related to clinical trial success and regulatory approval [sec_mda · as of 2026-03-27].
From the filings
Quoted directly from source documents.
Ampligen is an investigational drug with no FDA approval.
“Our drug and related technologies are investigational and subject to regulatory approval.”
SEC MD&A · March 27, 2026
The company has a history of operating losses and negative equity.
“We may continue to incur substantial losses and our future profitability is uncertain.”
SEC MD&A · March 27, 2026
Preclinical findings do not guarantee clinical efficacy.
“Results obtained in animal models do not necessarily predict results in humans.”
SEC filings · February 5, 2026
The company needs additional financing.
“We will require additional financing which may not be available.”
SEC MD&A · March 27, 2026
Catalyst timeline
- 2026-12-31 · Phase2_Topline · ampligen — Phase 2 Readout: ampligen — Topline data from a Phase 2 study of Ampligen will be reported, providing initial efficacy and safety signals.
- 2028-09-01 · Phase3_Topline · ropivacaine — Phase 3 Topline: Evaluation of Postoperative Recovery When Combining Intravenous Lidocaine With Ropivacaine Infiltrat — Topline results from a Phase 3 study evaluating ropivacaine in postoperative recovery will be released.
Risks & what to watch (4)›
Key risks
- Regulatory approval risk — Ampligen and other candidates are investigational; failure to obtain FDA approval would materially harm operations [sec_mda · as of 2026-03-27].
- Financing risk — The company requires additional financing that may not be available, threatening ongoing operations [sec_mda · as of 2026-03-27].
- Clinical trial risk — Clinical trials may not be successful or yield favorable data; animal model results may not predict human outcomes [sec · filed 2026-02-05].
- Profitability uncertainty — The company has incurred substantial losses and future profitability is uncertain [sec_mda · as of 2026-03-27].
What to watch
- Phase 2 topline readout for Ampligen expected by 2026-12-31 [catalyst].
- Phase 3 topline readout for ropivacaine expected by 2028-09-01 [catalyst].
- Ability to secure additional financing to support ongoing operations and trials [sec_mda · as of 2026-03-27].
- Regulatory updates or FDA interactions regarding Ampligen or other candidates [sec].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run AIM ImmunoTech Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AIM ImmunoTech Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
6.6 months
D/E 0.64 · 0% dilution
Lead: Approved
2 candidates
2 upcoming, next in ~123d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$52K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 29,918 | $18K |
| xtx topco ltd | 20,590 | $12K |
| jane street group, llc | 20,047 | $12K |
| vanguard fiduciary trust co | 17,519 | $10K |
| morgan stanley | 864 | $505 |
| harbour investments, inc. | 32 | $19 |
| creative financial designs inc /adv | 30 | $18 |
| hrt financial lp | 26,032 | $15 |
| osaic holdings, inc. | 15 | $7 |
| hoey investments, inc | 10 | $6 |
Showing top 10 of 14 institutional holders of AIM ImmunoTech Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 3.1%
- Days to cover
- 0.0
- Shares short
- 248,631
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AIM short interestGovernance
Frequently asked questions
What is the AI investment thesis for AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. is a clinical-stage biopharmaceutical company focused on developing its lead investigational drug, Ampligen, for viral diseases and cancers, with no approved products and a history of operating losses.
What is AIM ImmunoTech Inc.'s lead drug candidate?
AIM ImmunoTech Inc.'s most advanced tracked candidate is alferon n (Approved) for refractory or recurring external genital warts.
What is AIM ImmunoTech Inc.'s next catalyst?
AIM ImmunoTech Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: ampligen" — expected December 31, 2026.
Who is the CEO of AIM ImmunoTech Inc.?
Mr. Thomas K. Equels Esq., J.D., M.S. is the chief executive officer of AIM ImmunoTech Inc. (AIM).
Where is AIM ImmunoTech Inc. headquartered?
AIM ImmunoTech Inc. (AIM) is headquartered in Ocala, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.